Trial
UBX1325 ENVISION wet-AMD Phase 2
Executive intelligence snapshot
Current reviewed view
Earlier ocular work suggested that targeted senolysis could reduce treatment burden while preserving vision.
This profile includes 2 reviewed relationship(s) and 3 reviewed source(s).
This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.
Evidence state
Source-reviewed
Evidence state
What the evidence supports
Earlier ocular work suggested that targeted senolysis could reduce treatment burden while preserving vision.
Evidence boundary
Key limitations
- The sponsor reported a non-inferiority miss alongside maintained mean visual acuity and later exploratory supportive observations.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.
Not established
Key unknowns
- Unreported or unaccepted endpoints, effect estimates, population details, dose, route, and post-freeze results remain unknown.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.
Intelligence connections
Related intelligence
Reviewed source layer
Evidence & sources
These cards show only metadata present in the reviewed source registry.
bibliographic index
Multifocal Electroretinography Changes after UBX1325 Treatment in Neovascular Age-Related Macular Degeneration
PubMed
Reference: 39337030
Reviewed: 2026-08-06
filing system
Unity Biotechnology, Inc. 2024 Annual Report
U.S. SEC EDGAR
Reference: 1463361
Reviewed: 2026-08-06
trial registry
UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
ClinicalTrials.gov
Reference: NCT05275205
Reviewed: 2026-08-06
Evidence update
Pending review
Further evidence review is pending.
Technical provenance
- Object key
trial:LNPG-ENT-3e4d4901-9d5d-47df-a8ee-8c018f84c7c9- Source release
LNPG-REL-20260807-027- Mapping version
0.2.0- Presentation release
LNPG-REL-20260808-037- Projection hash
8503a6bf2ce6acf11d501e22ac9c29d065191c8bb30898aec74875315b62e144
Source identifiers
LNPG-SRC-3b165d43-b8d9-4956-aaa6-4b01460d6544LNPG-SRC-d9a27303-442b-423c-b752-95cf87597c15LNPG-SRC-df3da47f-0297-4219-8f9d-5bb050be51a8
Directed relationship identities
edge:00286—trial_exactly_links_companyedge:00290—trial_tests_intervention
Scores are not displayed because no score methodology is qualified for this profile.
Presentation contract
- Snapshot mode
DIRECT_GOVERNED_SUMMARY
Pending-state records
pending:00037—accepted_downstream_pending_context
Exposed separately; canonical facts unchanged.